Hence, by contrast with nonresponders, in IBD patients responding to anti-TNF therapy, the downregulation of CXCL12 and CXCL13 could result in reduced migration of lymphocytes to inflamed tissues. The gene discussed is CXCL13; the disease is inflammatory bowel disease.